Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Fieldview Capital Management LLC

Fieldview Capital Management LLC decreased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 76.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,514 shares of the biopharmaceutical company’s stock after selling 52,261 shares during the period. Fieldview Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $325,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in CPRX. Rothschild Investment LLC grew its stake in shares of Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,520 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 331.4% in the third quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 2,678 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 498 shares during the last quarter. Dakota Community Bank & Trust NA purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $81,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Catalyst Pharmaceuticals by 60.0% in the third quarter. PNC Financial Services Group Inc. now owns 9,366 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 3,511 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $24.41 on Thursday. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of 14.44, a price-to-earnings-growth ratio of 0.73 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $26.58. The stock has a 50-day simple moving average of $23.92 and a 200 day simple moving average of $22.44.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Citigroup raised their price target on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Two research analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $34.00.

Insider Buying and Selling

In other news, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director owned 2,360 shares in the company, valued at approximately $54,870. This trade represents a 91.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.40% of the stock is currently owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).